TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04079985

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Animal-assisted therapy
Description: The sessions were held in the primary care centre, and had specific objectives agreed in advance by the research team. The sessions had the following schedule: Session 1, lower extremities in sitting position; Session 2, upper extremities in sitting position; Session 3, cervical spine in sitting position; Session 4, dorsal spine in sitting position; Session 5, lumbar spine in sitting position; Session 6, Static Standing and Upper Extremities; Session 7, Static Standing; Sessions 8, 9, 10 and 11, Dynamic Standing; and Session 12, Safety Reinforcement.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animal-assisted therapy
Description: The sessions were held in the primary care centre, and had specific objectives agreed in advance by the research team. The sessions had the following schedule: Session 1, lower extremities in sitting position; Session 2, upper extremities in sitting position; Session 3, cervical spine in sitting position; Session 4, dorsal spine in sitting position; Session 5, lumbar spine in sitting position; Session 6, Static Standing and Upper Extremities; Session 7, Static Standing; Sessions 8, 9, 10 and 11, Dynamic Standing; and Session 12, Safety Reinforcement.
Study: NCT03898596

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ECG
Description: An ECG collects superficial readings of heart activity
Study: NCT02596646

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early Precut
Description: Early precut was performed during ERCP with difficult biliary cannulation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged cannulation attempts
Description: Prolonged cannulation attempts was performed during ERCP with difficult biliary cannulation
Study: NCT01452412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Description: 0.4 mEq/kg/day ideal body weight to be taken once a day
Study: NCT01954862

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Immersion/CO2
Description: Water Immersion during insertion, CO2 insufflation during withdrawal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Exchange/CO2
Description: Water Exchange during insertion, CO2 insufflation during withdrawal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Immersion/AI
Description: Water Immersion during insertion, AI insufflation during withdrawal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Exchange/AI
Description: Water Exchange during insertion, AI insufflation during withdrawal.
Study: NCT01452412

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: To be taken on the same schedule as the active arm
Study: NCT03539835

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Description: Resistance training (RT) will include 15 repetitions for two sets and to exhaustion on the third set for seven major muscle groups: the leg and chest press, knee extension, leg curl, row, abdominal crunch, and bicep curl. Resistance is gradually increased to account for strength gains when subjects are able to complete 20 repetitions on the third set.
Study: NCT02258711

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIMPLE 2.0
Description: SIMPLE 2.0 psychoeducative and self-monitoring smart-phone application plus treatment as usual.
Study: NCT01833663

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin Succinate Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin Succinate Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogen
Study: NCT04477291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG-806
Description: CG-806 will be given orally in ascending doses starting at 450 mg PO BID until the maximum tolerated dose or candidate recommended Phase 2 dose is reached.
Study: NCT02833987

Intervention type: DRUG
Intervention: Apixaban (ATC B01AF02)
Description: Exposure to apixaban (ATC B01AF02) will be defined as a new prescription for apixaban in the 30 days following the date of an incident VTE diagnosis.

Intervention type: DRUG
Intervention: Dabigatran (ATC B01AE07)
Description: Exposure to dabigatran (ATC B01AE07) will be defined as a new prescription for dabigatran in the 30 days following the date of an incident VTE diagnosis.

Intervention type: DRUG
Intervention: Rivaroxaban (ATC B01AF01)
Description: Exposure to rivaroxaban (ATC B01AF01) will be defined as a new prescription for rivaroxaban in the 30 days following the date of an incident VTE diagnosis.

Intervention type: DRUG
Intervention: Warfarin (ATC B01AA03)
Description: Exposure to warfarin (ATC B01AA03) will be defined as a new prescription for warfarin in the 30 days following the date of an incident VTE diagnosis.
Study: NCT03417778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: 100 mg tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: 100 mg tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: 100 mg tablet administered orally
Study: NCT01497769

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aerosol inhaled MVA85A
Description: Aerosol inhaled MVA85A 1 x 10\^7 pfu and intradermal saline placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intradermal MVA85A
Description: Intradermal MVA85A 1 x 10\^7 pfu and inhaled aerosol saline placebo
Study: NCT01843920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol-dorzolamide (Glaucoma drops)
Description: Patients will receive the standard post-operative drops regardless of what group you are in. The glaucoma drops will only be given to the experimental group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard post-operative topical drops
Description: Patients will receive the standard post-operative drops regardless of what group ther are in. The standard post-operative drops are Prednisolone acetate,Polymyxin B and Trimethoprim

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard post-operative topical drops
Description: Patients will receive the standard post-operative drops regardless of what group ther are in. The standard post-operative drops are Prednisolone acetate,Polymyxin B and Trimethoprim
Study: NCT02817360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAS-antagonist and beta-blocker up-to maximal dosages
Description: All patients have to be stable on their glucose lowering, lipid lowering and blood pressure lowering therapy at least for 3 months. RAS-antagonist and beta-blocker therapy at entrance is allowed. Patients receive a prescription and/or up-titration to maximum recommended or tolerated dose of RAS-antagonist and beta-blockers within three months of study entry. The Number of titration visits is up to the treating physician, but one visit should be performed at least at the end of titration.
Study: NCT01085760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Comparison of different doses of drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Comparison of different doses of drug
Study: NCT02817360

Intervention type: OTHER
Group type: OTHER
Intervention: RAS-antagonist and beta-blocker none or at stable dose
Description: All patients have to be stable on their glucose lowering, lipid lowering and blood pressure lowering therapy at least for 3 months. RAS-antagonist and beta-blocker therapy at entrance is allowed. Changes in RAS-antagonist or beta-blocker therapy are not allowed in the control group during the study phase. If there is a vital indication for changes, this has to be argued and documented.
Study: NCT03539835

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitively-based compassion training control (CBCT)
Description: Cognitively-based compassion training control (CBCT) classes will be performed in a group setting for 1.5-2 hours per week, and consist of didactics, class discussion, and guided meditation practice. Each class will begin with a period of meditation to calm and focus the mind, followed by analytical practices designed to challenge unexamined assumptions regarding feelings, and actions toward others with a focus on generating spontaneous empathy and compassion for themselves and others.
Study: NCT00187356

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radial Artery and Saphenous Vein Grafts Randomized to either right coronary or left circumflex coronary artery territories
Description: Each patient will receive both study grafts (Radial artery and Study Saphenous vein graft). The within-patient randomization scheme will dictate whether the radial goes to the right or circumflex territory. The saphenous vein graft will go to the opposing territory.
Study: NCT01820702

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Defined Training Programme
Description: A Smith Machine with fixed rails was used to guide the heel raise and squat exercises in the vertical axis. A metronome was used to direct the subjects during the performance of the exercises. Squats and heel raises were performed against body weight plus the additional weight of the barbell (15 kg). The heel raises were performed with straight knees and without ankle dorsiflexion. The shallow squats were performed continuously for 3 minutes. The hopping and the cross-hopping exercises were performed without Smith Machine. The bilateral hops were performed at \~ 3 repetitions per second with 15-s rest insertions between each set. Cross-hopping was performed continuously for 3 minutes against \~ 1.3 repetitions per second. Except for the duration of the static squat, with progressed from 45 s at HDT1 to 70 s at HDT5, none of the exercises were progressed during the study. Including the scheduled rest pauses, the LRT sessions were completed in 24 minutes.
Study: NCT04292795

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic Ultrasound
Description: The Intervention will be provided according to the set protocols used in previous literature.
Study: NCT01085760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Comparison of different doses of drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Comparison of different doses of drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Comparison of different drug doses
Study: NCT04292795

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short wave diathermy
Description: The Intervention will be provided according to the set protocols used in previous literature.
Study: NCT02060175

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cilotax drug-eluting stents implantation
Study: NCT00346983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaptanib sodium
Description: 0.3mg/0.1ml intravitreal injection, every 6 weeks, up to a total of 3 injections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Sham injection, every 6 weeks, up to a total of 3 sham injections
Study: NCT03907371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil Hydrochloride
Description: Donepezil will be used with a dosage of 5 milligram at 8 am for one week (Week 1), then 10 milligram at 8 am for 23 weeks (Week 2-24).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be used with a dosage of one half pill at 8 am for one week (Week 1), then one pill at 8 am for 23 weeks (Week 2-24).
Study: NCT00461253

Intervention type: DEVICE
Intervention: Levonorgestrel-releasing IUD
Description: This is a case-control-study; strictly speaking the category intervention type does not apply to this study.

Intervention type: DEVICE
Intervention: Levonorgestrel-releasing IUD
Description: This is a case-control-study; strictly speaking the category intervention type does not apply to this study.

Intervention type: DEVICE
Intervention: Copper IUD
Description: This is a case-control-study; strictly speaking the category intervention type does not apply to this study.

Intervention type: DEVICE
Intervention: Copper IUD
Description: This is a case-control-study; strictly speaking the category intervention type does not apply to this study.
Study: NCT03013816

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Organ Donation Education: Testimonial Messaging
Description: The testimonial messaging video intervention will be shown

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Organ Donation Education: Informational Messaging
Description: The informational messaging video intervention will be shown

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Organ Donation Education: Blended Messaging
Description: The blended messaging video intervention will be shown
Study: NCT02060175

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DESyne drug-eluting stents implantation
Study: NCT01443728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Vitamin D3 100,000 IU
Description: Oral vitamin D3, 100,000 IU \[2.5 mg\] given once a month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Vitamin D3 12,000 IU
Description: Standard dose oral vitamin D3 12,000 IU \[0.3 mg\] given once a month
Study: NCT02989909

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CATS tonometer prism
Description: demonstrate that not more than 5% of the paired differences between the reference tonometer (CATS prism) reading and the test tonometer (Goldmann prism) reading for each pressure range

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Goldmann tonometer prism
Description: demonstrate that not more than 5% of the paired differences between the reference tonometer (CATS prism) reading and the test tonometer (Goldmann prism) reading for each pressure range
Study: NCT03315195

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement (ONS)
Description: ONS supplement by 500 kcal/day for 14 days
Study: NCT04471415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRP-104
Description: DRP-104 administered intravenously over 1 hour, three times per week (TIW) (Monday, Wednesday, Friday) for 2 consecutive weeks, one week off~DRP-104 administered subcutaneously twice weekly (Monday/Thursday or Tuesday/Friday) every week OR thrice weekly (Monday, Wednesday, Friday) every week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRP-104
Description: DRP-104 administered intravenously over 1 hour, three times per week (TIW) (Monday, Wednesday, Friday) for 2 consecutive weeks, one week off~DRP-104 administered subcutaneously twice weekly (Monday/Thursday or Tuesday/Friday) every week OR thrice weekly (Monday, Wednesday, Friday) every week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRP-104
Description: DRP-104 administered intravenously over 1 hour, three times per week (TIW) (Monday, Wednesday, Friday) for 2 consecutive weeks, one week off~DRP-104 administered subcutaneously twice weekly (Monday/Thursday or Tuesday/Friday) every week OR thrice weekly (Monday, Wednesday, Friday) every week
Study: NCT03674398

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise+CT
Description: The exercise+CT group is asked to participate in 30 minutes of aerobic exercise followed by a 20-minute cognitive training (CT) program that targets attention and memory. Training will take place following exercise due to elevated levels of brain-derived neurotrophic factor and increased arousal, which is theorized to benefit cognitive task performance. Computerized CT exercises will be delivered using participants' smartphone. Adherence to the computerized CT program is monitored using electronic data upload after each training session. Participants are asked to engage in three sessions per week with the first week taking place in a lab-setting. Participants are asked to continue the aerobic exercise and CT program at home for the subsequent three weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise only
Description: The exercise only group will receive the same exercise prescription as the exercise+CT group. Participants in this group are asked to watch 20 minutes of health-related educational videos post-exercise. Videos are administered via participants' smartphones. After each video session, participants answer multiple-choice questions that assess engagement. Following the first week of treatment in-lab, participants are asked to continue watching health-related videos, post-exercise, for three weeks at home.
Study: NCT01901926

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non Surgical Periodontal Treatment
Description: one time intervention in the form of scaling and root planing
Study: NCT04471415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRP-104
Description: DRP-104 administered intravenously over 1 hour, three times per week (TIW) (Monday, Wednesday, Friday) for 2 consecutive weeks, one week off~DRP-104 administered subcutaneously twice weekly (Monday/Thursday or Tuesday/Friday) every week OR thrice weekly (Monday, Wednesday, Friday) every week
Study: NCT00641628

Intervention type: PROCEDURE
Intervention: mastectomy
Study: NCT04471415

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: atezolizumab administered intravenously over 1 hour at 1200 mg once every 3 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: atezolizumab administered intravenously over 1 hour at 1200 mg once every 3 weeks.
Study: NCT00580788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTHrP (1-36)
Description: IND # 49,175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTHrP (1-36)
Description: IND # 49,175
Study: NCT00311896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemiparin
Study: NCT01806194

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling
Description: Small changes behavioral counseling and social support, delivered in 16 sessions by community health workers

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Control Arm
Description: 16 mailings of diabetes educational materials but no regular contact with community health workers
Study: NCT01761383

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nintendo Wii video console and Nintendo Wii Fit Plus games
Description: The intervention will be provision of Nintendo Wii console and Wii Fit Plus video games to use for the duration of the study with no restrictions or limitations on the games participants are allowed to play or duration of play. There will be 5 home visits over a 6-month period to evaluate Nintendo Wii use and assess patients'health, functioning and quality of life.
Study: NCT02115490

Intervention type: DRUG
Intervention: Bisphosphonates
Study: NCT00198055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aripiprazole
Description: Aripiprazole 5 mg per day for 2 weeks, then can be increased to 10mg per day if tolerated for 2 weeks, then can be increased to 15 mg per day for 4 weeks.
Study: NCT00422825

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib
Study: NCT00690066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PROCHYMAL®
Description: Intravenous infusion of ex vivo cultured adult human mesenchymal stem cells

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion of excipients of PROCHYMAL®
Study: NCT01468350

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dalfampridine-ER 10mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dalfampridine-ER 10mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dalfampridine-ER 10mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dalfampridine-ER 10mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02595294

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical Lateral Glide neural mobilization
Description: Non-surgical non-invasive Cervical Lateral Glide neural mobilization procedure was applied by a physical therapist continuously during 2 minutes in 5 different occasions with 1 minute of rest between each 2 minute application of the Neural Mobilization technique. The intervention was applied during a period of 6 weeks. The correct linear alignment of patient's cervical spine was determined through the baseline use of a Universal Goniometer Device in each application of Cervical Lateral Glide neural mobilization.
Study: NCT01378325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Prophylactic variable rate of phenylephrine infusion started at 0.75 µg/kg/min vs saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Prophylactic variable rate of saline infusion where we adjusted the pump at a starting rate of 0.75 µg/kg/min, equivalent to 0.0075 mL/kg/min of saline
Study: NCT00311896

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02578784

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angioplasty with drug-coated balloon
Description: Angioplasty with drug-coated balloon Elutax (Aachen Resonance, Germany)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Angioplasty with plain old balloon
Description: Angioplasty with plain old balloon Sterling (BostonScientific, Switzerland)
Study: NCT03790657

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: practice of a complex walking task
Description: walking over obstacles

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: practice of a complex walking task
Description: walking over obstacles

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dosage A: transcranial direct current stimulation (tDCS)
Description: mild electrical stimulation delivered to the frontal region of the brain

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dosage B: transcranial direct current stimulation (tDCS)
Description: mild electrical stimulation delivered to the frontal region of the brain
Study: NCT01968642

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Study: NCT00980395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m2 IV Day 1. Repeat every 28 days for a maximum of 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: 1.3 mg/m2 IV Days 1 and 4. Repeat every 28 days for a maximum of 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cladribine
Description: 4 mg/m2 IV over 2 hours Days 1-5. Repeat every 28 days for a maximum of 6 cycles.